Nuhou Uea

Imi hou no na ma'i ma'i ma'i ma'i ma'i

i kakauia ma hoʻoponopono

ʻO Caris Life Sciences® e hōʻike i nā ʻike e hāʻawi i ka ʻike hohonu e pili ana ka hōʻike ʻana o nā ʻano genes e pili ana i ka nui o ka hoʻolaha ʻana i ka lāʻau lapaʻau, i hoʻopaʻa ʻia e ke kūlana p53, pili i nā hopena lapaʻau ma nā ʻano chemotherapeutic maʻamau i hoʻohana ʻia no ka mālama ʻana i ka maʻi kanesa colorectal metastatic (CRC). E hōʻike ʻia kēia mau hopena ma ka 2022 American Association for Cancer Research (AACR) Annual Meeting e mālama ʻia ana ʻApelila 8 - 13, 2022 ma New Orleans, Louisiana.

ʻO ka noiʻi me ka pepa i kapa ʻia, "Prognostic and predictive drug-induced gene signatures for colorectal cancer maʻi maʻi 'aʻai pilikino e pili ana i ke kūlana p53 a me ka mālama ʻana me FOLFOX, 5-FU, oxaliplatin a irinotecan" (Abstract #1231), i alakaʻi ʻia e Wafik El-Deiry , MD, Ph.D., FACP, Luna Hoʻokele o Legorreta Cancer Center o Brown University, Associate Dean ma ke Kula Lapaʻau Warren Alpert, he lālā o Caris 'Precision Oncology Alliance (POA). ʻO Caris 'POA kahi pūnaewele ulu nui o nā kikowaena maʻi maʻi maʻi ma ka honua holoʻokoʻa e hui pū ana e holomua i ka oncology pololei a me ka noiʻi biomarker-driven. Ke hōʻike ʻia nei kēia hana ma New Orleans e Lindsey Carlsen, he haumāna puka kula ʻo Pathobiology ma EL-DEIRY Lab ma Brown.

ʻO ka pahuhopu o kēia haʻawina ʻo ia ka ʻike ʻana i nā biomarkers wānana no nā chemotherapies i hoʻohana ʻia ma CRC. Ua hoʻohana ke aʻo ʻana i nā laina kelepona CRC e ʻike i nā ʻano genes i hōʻike ʻia ma hope o 5-fluorouracil, irinotecan, a i ʻole oxaliplatin lapaʻau a hoʻopaʻa ʻia nā pūlima ma muli o ke kūlana p53. Mai kēia mau haʻawina in vitro, ua nānā nā mea noiʻi inā hiki i kēia mau genes a me nā pūlima gene ke wānana i nā hopena maʻi CRC ma hope o ka chemotherapy (FOLFOX, 5-fluorouracil, irinotecan a i ʻole oxaliplatin). 2,983 wild-type a me 6,229 poho-o-hana p53 CRC maʻi laʻana i kālailai 'ia e DNA / RNA hope-hanauna sequencing ma Caris Life Sciences. Ua ʻike ʻia nā hopena ola o ka honua maoli mai ka ʻikepili hoʻopiʻi ʻinikua a me nā manaʻo ʻo Kaplan-Meier. He hopena koʻikoʻi ka hōʻike gene prognostic a me non-prognostic i nā hopena ola ma hope o nā lāʻau lapaʻau kūikawā.

"Ke kōkua nei kēia haʻawina iā mākou e hoʻomaopopo i ke koʻikoʻi o nā pūlima gene i ka hōʻike ʻana i kahi hiki ke wānana i hoʻonui ʻia i hoʻohālikelike ʻia me nā transcripts pākahi," wahi a El-Deiry. "Ke hoʻopili nei i ka noiʻi kumu a me ka noiʻi lapaʻau, ʻae kēia noiʻi iā mākou e hoʻomaopopo maikaʻi i nā lāʻau lapaʻau e ʻoi aku ka maikaʻi o ka poʻe maʻi CRC." Ua ʻike ʻia ka haʻawina ʻo ka hōʻike ʻana o nā ʻano genes e pili ana i ka hoʻolaha ʻana i ka lāʻau lapaʻau hiki ke wānana i nā hopena ma hope o ka mālama ʻana i ka chemotherapy:

• ʻO ka EGR1 kiʻekiʻe a me ka FOS mRNA e wānana kūʻokoʻa i ka pane ʻana i ka FOLFOX i nā maʻi me nā maʻi puʻupuʻu p53 ʻano hihiu.

• Hoʻopili ka mRNA CCNB1 haʻahaʻa me ka wānana maikaʻi o nā maʻi maʻi CRC me nā maʻi maʻi e mālama ana i ka TP53 nalowale o nā loli hana.

• Hōʻike haʻahaʻa haʻahaʻa o BTG2 i ka wānana maikaʻi aʻe i nā maʻi me ka MSI-High TP53 mutated tumors.

Hiki i nā pūlima Gene ke hōʻike i ka hiki ke wānana i hoʻohālikelike ʻia me nā hopena transcript pākahi.

"Ke nānā aku nei ʻo Caris i nā biomarkers e hiki ke wānana i ka pane ʻana o ka maʻi i nā lāʻau lapaʻau hou loa, akā hoʻāʻo ʻia a me nā chemotherapies ʻoiaʻiʻo e like me FOLFOX," wahi a W. Michael Korn, MD, Luna Nui o ka Lapaʻau ma Caris. "Ua hauʻoli mākou i ka ʻike ʻana i ka hiki ke noiʻi unuhi i hoʻoikaika ʻia e ka nui o nā ʻikepili multi-omic a me nā mea hana analytical a Caris i hoʻomohala a hoʻomau i ka holomua."

Hoʻopili ka molecular profiling holoʻokoʻa o Caris i ka exome holoʻokoʻa (DNA), ka transcriptome holoʻokoʻa (RNA) a me ka ʻōlelo protein, e hāʻawi ana i kahi kumuwaiwai like ʻole a me ke ala kūpono i mua e alakaʻi i ka noiʻi unuhi e hoʻolōʻihi i ka ʻike no ka ʻike ʻana, ka ʻike, ka nānā ʻana, ke koho ʻana a me ka hoʻomohala lāʻau. e hoʻomaikaʻi i ke kūlana kanaka.

E hōʻike ana ʻo Caris i nā ʻikepili hou mai nā haʻawina e hōʻike ana i ke kuleana koʻikoʻi o ka lāʻau lapaʻau pololei a me ka molecular profiling i ka mālama ʻana i ka maʻi kanesa. E loaʻa nā hōʻike a pau ma ka pūnaewele ma o ka punaewele Caris e hoʻomaka ana i ka lā 8 ʻApelila 2022.

Hōʻike ʻia nā hōʻike hou aku i ka hopena o ka hoʻopili ʻana i ka molecular comprehensive a me ka hiki ke hoʻokō ʻia

• 'O ka hō'ailona piha o ka FGF/FGFR nā ho'ololi i nā ma'i ma'i umauma invasive (Abstract #5793) 'O ka hō'ailona FGFR ke kikowaena no ka ho'onui'ana o ka ma'i kanesa, ka ne'e, ka angiogenesis a me ke ola; Ua lilo nā hoʻololi FGFR i mea hiki ke hana maʻi i ka hoʻonui ʻana i nā ʻano maʻi maʻi. Ua loiloi kēia haʻawina i ka hanana a me ke ʻano o nā hoʻololi FGF/FGFR ma luna o 12,000 invasive breast cancers a hōʻike i ka heterogeneity nui o nā hoʻololi FGF/FGFR i nā ʻano histologic a me nā molecular subtypes a me nā wahi metastatic ʻokoʻa o ka maʻi maʻi umauma. Eia hou, ua hōʻike ʻia nā hui o nā hoʻololi FGFR a me ke kū'ē ʻana i nā lāʻau lapaʻau i loko o kahi waihona lapaʻau nui me nā hopena molekala.

• Nā hiʻohiʻona genomic a me ka immune o nā subtypes EGFR i loko o ka maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi (NSCLC) (Abstract #4119) ʻOiai ʻo EGFR mutant NSCLC maʻamau e kū kūʻē i nā mea hoʻopaneʻe PD-1/PD-L1, hiki i kahi ʻāpana liʻiliʻi o nā maʻi ke loaʻa nā pane lōʻihi. . Hōʻike nā ʻōpū EGFR-mutant i ka heterogeneity molecular koʻikoʻi, akā naʻe, aia ka nele o ka maopopo o ka genomic a me ka immune profiles o EGFR mutation subtypes, a ʻo ka hoʻomaʻamaʻa hou aʻe o kēia hiki ke kōkua i ka ʻike ʻana i nā mea maʻi e pane i nā lāʻau lapaʻau. Ke hoʻohana nei i ka ʻikepili molecular multi-omic i hana ʻia e Next-Generation Sequencing o DNA a me RNA ma kahi hui nui o nā maʻi maʻi NSCLC, ua hōʻoia kēia haʻawina i ka emi ʻana o ka immunogenicity e pili ana me ka hapa nui o nā ʻano like ʻole o nā mutations EGFR i hōʻike ʻia e nā biomarkers me PD-L1, TMB a me CD8 + T ke komo ʻana o ke kelepona; a hōʻike i nā hoʻololi ʻokoʻa EGFR e pili ana me ka ʻaoʻao immune maikaʻi e hōʻike ana i ka pane ʻana i ka lāʻau lapaʻau.

Hoʻolapala, PDF & Email

Pūnaewele

No ka mea kākau

hoʻoponopono

ʻO Linda Hohnholz ka Lunahooponopono no eTurboNew. Aia ʻo ia ma ka eTN HQ ma Honolulu, Hawaii.

Waiho i ka manaʻo